Inolimomab Biosimilar – Anti-IL2RA mAb – Research Grade

Description of Inolimomab Biosimilar - Anti-IL2RA mAb - Research Grade

Introduction

Inolimomab Biosimilar, also known as Anti-IL2RA mAb, is a monoclonal antibody that targets the interleukin-2 receptor alpha (IL-2RA). This receptor is found on the surface of T cells and plays a crucial role in the immune response. Inolimomab Biosimilar is a research grade antibody that has potential therapeutic applications in various diseases. In this article, we will discuss the structure, activity, and potential applications of Inolimomab Biosimilar.

Structure of Inolimomab Biosimilar

Inolimomab Biosimilar is a recombinant humanized monoclonal antibody derived from the mouse hybridoma cell line. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 150 kDa. The heavy chain consists of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chain consists of two constant domains (CL and CL’) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the IL-2RA receptor.

Activity of Inolimomab Biosimilar

Inolimomab Biosimilar specifically binds to the IL-2RA receptor on the surface of T cells. This binding prevents the interaction of IL-2RA with its ligand, interleukin-2 (IL-2). IL-2 is a cytokine that plays a crucial role in the activation and proliferation of T cells. By blocking the IL-2RA receptor, Inolimomab Biosimilar inhibits the signaling pathway that leads to T cell activation and proliferation.

In addition to its activity on T cells, Inolimomab Biosimilar has also been shown to modulate the function of other immune cells, such as B cells and natural killer cells. This multi-target activity makes Inolimomab Biosimilar a potential therapeutic agent for various diseases involving dysregulated immune responses.

Applications of Inolimomab Biosimilar

1. Autoimmune diseases Inolimomab Biosimilar has been studied as a potential treatment for autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and psoriasis. These diseases are characterized by an overactive immune response, and Inolimomab Biosimilar’s ability to modulate various immune cells makes it a promising therapeutic target.

2. Organ transplant rejection

Organ

transplant rejection occurs when the recipient’s immune system recognizes the transplanted organ as foreign and attacks it. Inolimomab Biosimilar has been shown to reduce the risk of acute rejection in kidney transplant patients by inhibiting the activation and proliferation of T cells.

3. Graft-versus-host disease (GVHD) GVHD is a complication that can occur after a bone marrow or stem cell transplant, where the transplanted cells attack the recipient’s tissues. Inolimomab Biosimilar has been studied as a potential treatment for GVHD, as it can modulate the function of both T cells and natural killer cells, which play a role in the development of GVHD.

4.

Cancer

Inolimomab Biosimilar has also been investigated as a potential therapy for cancer. IL-2RA is overexpressed on the surface of many cancer cells, and by targeting this receptor, Inolimomab Biosimilar can inhibit the growth and proliferation of these cells. It has shown promising results in preclinical studies for the treatment of various types of cancer, including lymphoma and leukemia.

Conclusion

Inolimomab Biosimilar, also known as Anti-IL2RA mAb, is a research grade monoclonal antibody with potential therapeutic applications in various diseases. Its structure, activity, and multi-target effects make it a promising therapeutic target for autoimmune diseases, organ transplant rejection, GVHD, and cancer. Further research and clinical trials are needed to fully explore the potential of Inolimomab Biosimilar as a therapeutic agent.